The Food and Drug Administration has cleared Zydus Cadila’s liothyronine sodium tablets in dosage strengths of 5 mcg, 25 mcg, and 50 mcg. The product is the generic of Pfizer’s Cytomel tablets.

A large Swedish study shows those treated with LT3 in combination with LT4 for hypothyroidism have no greater breast cancer risk than individuals taking LT4 alone.